In 2023, the mortality due to prostate malignant neoplasms in Japan stood at 13.42 thousand male deaths. From 2024 to 2028, forecasts indicate a year-on-year increase, with mortality rising from 13.65 to 14.51 thousand male deaths. This reflects an annual growth rate of approximately 1.2% per year. The five-year compound annual growth rate (CAGR) from 2024 to 2028 is estimated at 1.55%, highlighting a consistent upward trend in mortality figures.
Future trends to monitor include advancements in medical technology, screening practices, healthcare policies, and potential socioeconomic changes, which may influence the trajectory of prostate cancer mortality in Japan.
